SVRA

Savara, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website avarapharma.com
Employees(FY) 28
ISIN US8051111016

Performance

-3.58%

+9.86%

-30.39%

-15.67%

-31.28%

YTD

-28.54%

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of SVRA 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend leans...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SVRA

Stock Rank

Recent News & Updates

2024-12-18 17:07
Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate(MT Newswires)
2024-12-18 16:05
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Business Wire)
2024-12-18 03:05
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Businesswire)
2024-12-17 16:05
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference(Business Wire)
2024-12-17 03:05
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference(Businesswire)
2024-11-25 09:18
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)(Simply Wall St.)
2024-11-22 16:05
Savara Announces New Employment Inducement Grant(Business Wire)
2024-11-22 08:05
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024(Business Wire)
2024-11-22 03:05
Savara Announces New Employment Inducement Grant(Businesswire)
2024-11-21 19:05
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024(Businesswire)
2024-11-21 06:20
Daily – Vickers Top Buyers & Sellers for 11/21/2024(Argus Research)
2024-11-19 06:38
Daily – Vickers Top Buyers & Sellers for 11/19/2024(Argus Research)
2024-11-18 12:37
Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing(MT Newswires)
2024-11-13 13:21
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate(GuruFocus.com)
2024-11-13 08:05
Savara Announces Participation in Upcoming Healthcare Conferences(Business Wire)
2024-11-12 19:05
Savara Announces Participation in Upcoming Healthcare Conferences(Businesswire)
2024-11-12 08:05
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update(Business Wire)
2024-11-11 19:05
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-11-04 16:05
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference(Business Wire)
2024-11-04 03:05
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference(Businesswire)
2024-10-22 08:05
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV(Business Wire)
2024-10-21 20:05
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV(Businesswire)
2024-10-18 16:05
Savara Announces New Employment Inducement Grant(Business Wire)
2024-10-18 04:05
Savara Announces New Employment Inducement Grant(Businesswire)
2024-10-01 08:05
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting(Business Wire)
2024-09-30 20:05
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting(Businesswire)
2024-09-27 08:53
Savara Initiates Early Access Program for Rare Lung Disease Treatment(MT Newswires)
2024-09-27 08:05
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Business Wire)
2024-09-27 04:05
Savara Announces New Employment Inducement Grant(Businesswire)
2024-09-26 20:05
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Businesswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.